Premier Health Approves Leadership and Stock Plan at 2026 AGM
Premier Health Approves Leadership and Stock Plan at 2026 AGM
Premier Health Approves Leadership and Stock Plan at 2026 AGM
Premier Health of America Inc. held its annual general meeting on March 26, 2026. The Canadian healthtech company, known for its LiPHe digital platform, put several key proposals to its shareholders for approval. At the meeting, shareholders voted on multiple resolutions. All matters presented were approved, including the election of three directors: Pierre-Luc Toupin, Hubert Marleau, and Jean-Robert Pronovost. The company also secured approval for its incentive Stock Option Plan, ensuring its continuation.
A total of 20,032,107 common shares were cast, accounting for 36.08% of the total shares issued. Additionally, shareholders re-appointed Raymond Chabot Grant Thornton LLP as the company's auditor. Premier Health specialises in outsourced healthcare solutions and digital transformation. Its LiPHe platform is designed to improve patient access by offering faster, more affordable, and widely available care services.
The annual general meeting concluded with all proposed measures passing successfully. The company will now move forward with its approved leadership, auditor, and stock option plan in place. No immediate updates on market performance are available following the meeting.
Biysk's Emergency Services Handle 1,783 Calls in One Week
From strokes to road accidents, Biysk's paramedics faced relentless pressure. Yet 113 calls were canceled—why did patients refuse help?
Abuja's new road project sparks debate as doctors decry failing hospitals
A shiny new road divides Abuja—while doctors warn lives are at risk in crumbling hospitals. Who gets priority in Nigeria's capital?
Heartseed loses Novo Nordisk backing for groundbreaking heart failure therapy
A promising cardiac treatment now stands alone. After Novo Nordisk's abrupt exit, Heartseed must navigate Phase 2 trials—and an uncertain future—without its pharma giant ally.
Groundbreaking trial tests twice-yearly injection for stubborn high blood pressure
Could a simple injection every six months transform hypertension care? Roche's $300M-backed trial seeks answers for patients who struggle with current treatments.